

Interim results good for Array drug

BOULDER - Array BioPharma Inc.'s breast-cancer fighting drug has received positive interim results during a phase 1 trial.

Boulder-based Array (Nasdaq: ARRY) is testing ARRY-380, an HER2 inhibitor drug, in cancer patients. HER2, also known as Human Epidermal growth factor Receptor 2 or ErbB2, is a protein that's often found in excess among cancer patients.

The interim results show that ARRY-380 demonstrated tumor regression in eight of 10 pretreated patients with HER2 expressing cancers. The patients were given at least 20-milligram doses of the drug. Of those eight, four experienced prolonged stable disease for 16 weeks or more.

"In preclinical studies, ARRY-380 was superior in reducing tumor size when compared to selective HER2 inhibitors, such as trastuzumab, and was active when combined with other standard-of-care therapies," Kevin Koch, the company's president and chief scientific officer, said in a statement.

The maximum tolerated dose of the drug in the phase 1 trial hasn't been achieved, and the study is ongoing.